EGFR and colorectal carcinoma: Although the predictive role of KRAS mutations, and more recently also BRAF mutations to recognize resistance to anti-EGFR therapy in advanced CRC patients has been accepted widely [3–7], the prognostic role of KRAS mutations in CRCs for survival is still controversial [8–12].